Get the Stockscreener App
35.02
1.46%
-0.52
Xenon Pharmaceuticals Inc stock is traded at $35.02, with a volume of 1.05M.
It is down -1.46% in the last 24 hours and up +10.86% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$35.54
Open:
$35.82
24h Volume:
1.05M
Relative Volume:
1.55
Market Cap:
$2.93B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-12.78
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-8.52%
1M Performance:
+10.86%
6M Performance:
-22.18%
1Y Performance:
-17.58%
1-Day Range:
$34.97
$36.40
1-Week Range:
$34.47
$38.47
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
35.02 | 2.93B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Barclays PLC - Defense World
Ratio Analysis: Unpacking Xenon Pharmaceuticals Inc (XENE)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Chardan Capital Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - Nasdaq
XENE: Chardan Capital Initiates Coverage with Buy Rating and $55 Price Target | XENE Stock News - GuruFocus
Chardan Initiates Xenon Pharmaceuticals at Buy With $55 Price Target - marketscreener.com
XENE: Chardan Starts Coverage with Positive Outlook and $55 Target | XENE Stock News - GuruFocus
Raymond James Financial Inc. Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Receives Outperform Rating from William Blair - Defense World
Xenon Pharmaceuticals to Announce Q1 2025 Financial Results - TipRanks
Xenon to Report Q1 2025 Financial Results on May 12, 2025 - The Manila Times
Xenon Q1 Earnings Preview: Key Updates Expected on Breakthrough Epilepsy Drug Azetukalner - Stock Titan
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - Yahoo Finance
(XENE) On The My Stocks Page - news.stocktradersdaily.com
Renaissance Technologies LLC Decreases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This trade activity should not be overlooked: Xenon Pharmaceuticals Inc (XENE) - Sete News
Xenon Pharmaceuticals Expands Team with $3M Equity Package: 78,600 Options Granted to New Hires - Stock Titan
Upward Trajectory: Xenon Pharmaceuticals Inc (XENE) Posts a Slidee, Closing at 38.20 - DWinneX
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc [XENE] MORTIMER IAN sells 22,468 Shares for $0.9 million - knoxdaily.com
Geode Capital Management LLC Purchases 720 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Envestnet Asset Management Inc. Sells 1,539 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenon Pharmaceuticals Inc (NASDAQ:XENE)’s 12-Month Price Target Currently Stands At 42 - Marketing Sentinel
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Wells Fargo & Company MN Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Market Insights: Xenon Pharmaceuticals Inc (XENE)’s Notable Gain of 2.34, Closing at 37.59 - DWinneX
Xenon Pharmaceuticals Inc (XENE) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Hold Rating - Defense World
When (XENE) Moves Investors should Listen - news.stocktradersdaily.com
The Goldman Sachs Group Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon- A Later Stage Story (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Q1 EPS Forecast for Xenon Pharmaceuticals Raised by Analyst - Defense World
Xenon Pharmaceuticals: Undervalued Stock with Promising Catalysts and Growth Potential - TipRanks
StockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Sell - Defense World
Sodium Channel Blockers Clinical Trial Pipeline Accelerates - GlobeNewswire
XENE stock touches 52-week low at $28.51 amid market shifts By Investing.com - Investing.com South Africa
XENE stock touches 52-week low at $28.51 amid market shifts - Investing.com
JPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Prudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Raymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):